Bioequivalence Study of a Fixed-dose Combination (FDC) of Dolutegravir (DTG) and Rilpivirine (RPV)
Phase 1
Completed
- Conditions
- Infection, Human Immunodeficiency VirusHIV Infections
- Interventions
- First Posted Date
- 2016-04-18
- Last Posted Date
- 2019-07-15
- Lead Sponsor
- ViiV Healthcare
- Target Recruit Count
- 118
- Registration Number
- NCT02741557
- Locations
- πΊπΈ
GSK Investigational Site, Overland Park, Kansas, United States
Relative Bio-availability Study of Dolutegravir and Lamivudine Fixed Dose Combinations
Phase 1
Completed
- Conditions
- Infection, Human Immunodeficiency Virus
- Interventions
- Drug: Dolutegravir/Lamivudine 50 mg/300 mg Tablet (Product Code AA)Drug: Dolutegravir/Lamivudine 50 mg/300 mg Tablet (Product Code AB)
- First Posted Date
- 2016-04-14
- Last Posted Date
- 2017-01-18
- Lead Sponsor
- ViiV Healthcare
- Target Recruit Count
- 30
- Registration Number
- NCT02738931
- Locations
- πΊπΈ
GSK Investigational Site, Overland Park, Kansas, United States
A Study to Evaluate the Effect of BMS-955176 on Pharmacokinetics of Dolutegravir and the Effect of Dolutegravir on the Pharmacokinetics of BMS-955176
Phase 1
Completed
- Conditions
- Infection, Human Immunodeficiency Virus
- Interventions
- First Posted Date
- 2016-03-22
- Last Posted Date
- 2017-01-19
- Lead Sponsor
- ViiV Healthcare
- Target Recruit Count
- 14
- Registration Number
- NCT02715479
- Locations
- πΊπΈ
GSK Investigational Site, Austin, Texas, United States
A Study of the Pharmacokinetics and Safety of BMS-663068 Administered in Subjects With Normal Renal Function and With Mild, Moderate, Severe and End Stage Renal Dysfunction (ESRD)
Phase 1
Completed
- Conditions
- HIV Infections
- Interventions
- Drug: Oral BMS-663068 (pro-drug)
- First Posted Date
- 2016-02-04
- Last Posted Date
- 2018-05-15
- Lead Sponsor
- ViiV Healthcare
- Target Recruit Count
- 30
- Registration Number
- NCT02674581
- Locations
- πΊπΈ
GSK Investigational Site, Miami, Florida, United States
A Study to Assess the Drug-drug Interaction of BMS 663068 With Methadone and Also With Buprenorphine/Naloxone
Phase 1
Completed
- Conditions
- Infection, Human Immunodeficiency Virus
- Interventions
- First Posted Date
- 2016-01-28
- Last Posted Date
- 2017-08-09
- Lead Sponsor
- ViiV Healthcare
- Target Recruit Count
- 32
- Registration Number
- NCT02666001
- Locations
- πΊπΈ
GSK Investigational Site, Overland Park, Kansas, United States
A Study to Assess the Effect of High Fat Meal and Increased Gastric pH on the Bioavailability of an Extended Release Formulation of BMS-663068 in Healthy Subjects
- First Posted Date
- 2016-01-28
- Last Posted Date
- 2017-09-11
- Lead Sponsor
- ViiV Healthcare
- Target Recruit Count
- 72
- Registration Number
- NCT02666053
- Locations
- πΊπΈ
GSK Investigational Site, Austin, Texas, United States
A Phase IV, Open Label, 4-period Cross-over Study to Investigate a Drug Interaction Between Lamivudine and Sorbitol Oral Solutions in Healthy Volunteers
Phase 4
Completed
- Conditions
- Infection, Human Immunodeficiency Virus
- Interventions
- First Posted Date
- 2015-12-17
- Last Posted Date
- 2017-05-15
- Lead Sponsor
- ViiV Healthcare
- Target Recruit Count
- 16
- Registration Number
- NCT02634073
- Locations
- πΊπΈ
GSK Investigational Site, Overland Park, Kansas, United States
THE EFFECT OF CYP3A5 GENOTYPE ON THE PHARMACOKINETICS OF MARAVIROC
Phase 1
Completed
- Conditions
- Healthy Subjects
- Interventions
- First Posted Date
- 2015-12-09
- Last Posted Date
- 2017-04-17
- Lead Sponsor
- ViiV Healthcare
- Target Recruit Count
- 47
- Registration Number
- NCT02625207
- Locations
- πΊπΈ
Pfizer New Haven Clinical Research Unit, New Haven, Connecticut, United States
Taste Properties of HIV Inhibitor
- First Posted Date
- 2015-11-20
- Last Posted Date
- 2018-04-17
- Lead Sponsor
- ViiV Healthcare
- Target Recruit Count
- 8
- Registration Number
- NCT02608918
- Locations
- πΊπΈ
GSK Investigational Site, Woburn, Massachusetts, United States
Study on Effects of BMS-955176 on the Pharmacokinetics of Probe Substrates
Phase 1
Completed
- Conditions
- HIV Infections
- Interventions
- Drug: CYP and transporter probe substrates
- First Posted Date
- 2015-10-16
- Last Posted Date
- 2018-07-13
- Lead Sponsor
- ViiV Healthcare
- Target Recruit Count
- 59
- Registration Number
- NCT02578277
- Locations
- πΊπΈ
GSK Investigational Site, Austin, Texas, United States
Β© Copyright 2025. All Rights Reserved by MedPath